Rep. Gilbert Ray Cisneros, Jr. Buys BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

Key Points

• Representative Gil Cisneros, Jr. purchased shares of BridgeBio Pharma (NASDAQ:BBIO) valued between $1,001 and $15,000 on August 8th, as disclosed in a filing.
• BridgeBio Pharma's stock price recently reached $51.49, showing a 0.0% change, with a market capitalization of approximately $9.84 billion.
• Several brokerages have set price targets for BridgeBio Pharma, with an average target of $63.94 and 17 analysts rating it as a Buy.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on September 12th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on August 8th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Chart Industries NYSE: GTLS on 9/2/2025.
• Purchased $1,001 - $15,000 in shares of Avient NYSE: AVNT on 9/2/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/27/2025.
• Sold $1,001 - $15,000 in shares of Amdocs NASDAQ: DOX on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Intapp NASDAQ: INTA on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of APi Group NYSE: APG on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Waters NYSE: WAT on 8/26/2025.
• Purchased $1,001 - $15,000 in shares of Semtech NASDAQ: SMTC on 8/26/2025.
• Sold $1,001 - $15,000 in shares of Fortive NYSE: FTV on 8/26/2025.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO traded up $2.04 during trading hours on Thursday, reaching $53.22. The company's stock had a trading volume of 457,751 shares, compared to its average volume of 2,922,959. The stock has a 50 day moving average price of $48.97 and a two-hundred day moving average price of $40.62. BridgeBio Pharma, Inc. has a 12 month low of $21.72 and a 12 month high of $54.60. The company has a market capitalization of $10.17 billion, a P/E ratio of -12.99 and a beta of 1.25.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The business had revenue of $110.57 million for the quarter, compared to analyst estimates of $98.46 million. During the same quarter in the prior year, the company earned ($0.39) earnings per share. The company's revenue was up 4999.9% on a year-over-year basis. As a group, analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BBIO. Piper Sandler lifted their price target on shares of BridgeBio Pharma from $63.00 to $68.00 and gave the stock an "overweight" rating in a report on Monday, July 14th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $95.00 price target on shares of BridgeBio Pharma in a report on Tuesday, July 29th. Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $67.00 to $76.00 and gave the stock an "overweight" rating in a report on Monday, June 30th. Citigroup lifted their price target on shares of BridgeBio Pharma from $58.00 to $67.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Finally, Scotiabank boosted their price objective on shares of BridgeBio Pharma from $55.00 to $57.00 and gave the company a "sector outperform" rating in a report on Wednesday, August 6th. Seventeen research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $63.94.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BBIO. Cetera Investment Advisers acquired a new position in BridgeBio Pharma during the fourth quarter valued at $1,020,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BridgeBio Pharma by 4.0% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 89,994 shares of the company's stock valued at $2,468,000 after purchasing an additional 3,481 shares during the period. ProShare Advisors LLC lifted its position in BridgeBio Pharma by 28.8% during the fourth quarter. ProShare Advisors LLC now owns 48,539 shares of the company's stock valued at $1,332,000 after purchasing an additional 10,864 shares during the period. Rafferty Asset Management LLC lifted its position in BridgeBio Pharma by 2.8% during the fourth quarter. Rafferty Asset Management LLC now owns 250,242 shares of the company's stock valued at $6,867,000 after purchasing an additional 6,911 shares during the period. Finally, Sphera Funds Management LTD. lifted its position in BridgeBio Pharma by 7.4% during the fourth quarter. Sphera Funds Management LTD. now owns 905,279 shares of the company's stock valued at $24,841,000 after purchasing an additional 62,635 shares during the period. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at BridgeBio Pharma

In related news, CEO Neil Kumar sold 40,000 shares of the business's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $45.45, for a total transaction of $1,818,000.00. Following the completion of the transaction, the chief executive officer directly owned 935,686 shares in the company, valued at $42,526,928.70. The trade was a 4.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Thomas Trimarchi sold 42,237 shares of the business's stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $49.48, for a total transaction of $2,089,886.76. Following the transaction, the chief financial officer owned 421,081 shares of the company's stock, valued at $20,835,087.88. This represents a 9.12% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 4,202,620 shares of company stock valued at $187,174,970 over the last ninety days. Corporate insiders own 18.20% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.